***Background.*** *Staphylococcus aureus* is a common cause of bacteremia in adults and children. There are published adult guidelines for *S. aureus* bacteremia management, but there are limited comparative effectiveness data to inform pediatric treatment guidelines. Describing the clinical characteristics and outcomes of pediatric inpatients with *S. aureus* bacteremia is necessary to prioritize future comparative effectiveness studies.

***Methods.*** An observational cohort of children \>2 months and \<19 years was assembled using Premier Perspective^TM^ Database, a nationally representative administrative database of billing and microbiology data. All incident admissions between 2009 and 2012 with lab-confirmed *S. aureus* bacteremia were included. Outside facility transfer patients were excluded. Admissions with a positive blood culture in the first 3 days were considered community-onset (CO); those beyond 3 days were considered healthcare-onset (HO). Two infectious diseases physicians independently reviewed all ICD-9 codes per admission to determine the source of bacteremia; subsequent reviewer discussion adjudicated disagreements. Wilcoxon rank-sum and Chi squared tests were used to compare medians and proportions, respectively.

***Results.*** There were 414 patients with *S. aureus* bacteremia; median age was 6.5 years (IQR: 1 to 13 years). Patients were more frequently white (n = 218, 53%), male (n = 261, 63%) and had CO infection (n= 368, 89%). Length of stay (LOS) after onset of bacteremia was longer for patients with HO (HO: 14 days, IQR: 5 to 28 vs CO: 5 days, IQR: 3 to 9; p \<0.001). The source of bacteremia was determined in 346 patients (84%) and was most commonly a bone/joint (HO: n = 14, 30%; CO: n = 140, 38%), skin/soft tissue (HO: n = 8, 17%; CO: n = 71, 19%), or pneumonia (HO: n = 5, 11%; CO: n = 40, 11%). The HO case fatality rate was higher than for CO (11% vs 2%, p = 0.0038).

***Conclusion.*** This is the first large, multi-center study of pediatric *S. aureus* bacteremia. CO bacteremia was more common, but HO bacteremia patients had longer LOS and higher case fatality rates. Future analyses will explore the impact of treatment strategies on patient outcomes.
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